Harbour BioMed
Tracked across 4 events · 25 articles · First seen Jun 10, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Harbour BioMed's IND application for HBM7004 has been accepted by the China — National Medical Products Administration (NMPA) of China, which is a positive step towards clinical evaluation in China and could enhance its market position in oncology therapeutics.
Jun 10, 2026 · 7 articles
Business
Impact: Harbour BioMed appointed Dhavalkumar Patel>>> as a Scientific Advisor, which is expected to enhance its immunology pipeline and drug development capabilities.
Jun 12, 2026 · 6 articles
Business
Impact: Harbour BioMed secured a complete victory in its patent infringement lawsuit against Amgen and Teneobio, validating its proprietary transgenic rodent technology and entitling it to $20.2 million in damages, with potential for up to $60.6 million. This strengthens its position as an innovator in the antibody technology field.
Jun 15, 2026 · 6 articles
Business
Solstice Oncology, a clinical-stage immuno-oncology company focused on neoadjuvant cancer treatment, launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion Ventures and other investors. The…
Impact: Harbour BioMed discovered and developed porustobart and licensed it to Solstice Oncology outside Greater China in February 2026; the launch and financing validate its antibody platform and could bring milestone and royalty revenue.
Sep 09, 2026 · 6 articles
85
Harbour BioMed licensed porustobart Solstice OncologySolstice Oncology $225M...
70
Harbour BioMed reported Phase 2 resultsSolstice Oncology $225M...
ERGEN INTELLIGENCE
Track Harbour BioMed live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard